Wednesday, March 05, 2025 | 12:35 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Zydus wins patent battle, can now launch ulcerative colitis drug in US

American court says proposed generic version of Lialda (mesalamine) is not a case of infringement

Zydus wins patent battle in US court; paves way for generic Lialda launch
Premium

Zydus

BS Reporter BS Reporter
Ahmedabad-based pharma major Cadila Healthcare on Wednesday said it has received a favourable judgement from a US federal court in a patent infringement case in favour of its US subsidiary, Zydus Pharmaceuticals (USA) Inc. This basically paves the way for the company to launch a generic drug to treat ulcerative colitis in the US market.

Zydus, however, did not comment on when it planned to launch the product in the US. It was the first pharmaceutical company to file an abbreviated new drug application (ANDA) for a generic version of Lialda. Shire has reported annual sales of $714 million for

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in